At the European Society for Medical Oncology (ESMO) Asia 2015 Congress, held in Singapore from 18 December to 21 December 2015, Sibylle Loibl, MD, PhD, from the German Breast Group, Neu-Isenburg, Germany, discusses changes in tumor expression of HER2 and hormone receptor status and pathological complete response (pCR) after neoadjuvant chemotherapy in a Japanese breast cancer registry.